The Latest Analyst Ratings for 10x Genomics
Portfolio Pulse from Benzinga Insights
Analysts have updated their ratings for 10x Genomics (NASDAQ:TXG) in the last quarter, with 2 bullish, 1 somewhat bullish, 1 indifferent, and no bearish ratings. The average 12-month price target for TXG is $57.75, a 13.24% increase from the previous target of $51.00. The high target is $70.00 and the low is $47.00. Analysts' opinions are based on company financials, meetings, and insider information, and are updated quarterly.
December 14, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics has received an updated average 12-month price target of $57.75, reflecting a 13.24% increase from the previous target, with a high estimate of $70.00 and a low of $47.00.
The increase in the average price target for 10x Genomics suggests a positive outlook from analysts, which could lead to increased investor confidence and a potential short-term rise in the stock price. The lack of bearish ratings and the presence of bullish and somewhat bullish ratings further support the potential for a positive impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100